Dr. Dennis D. Kim M.B.A., M.D., MBA Net Worth

The estimated Net Worth of Dennis D Kim is at least $4.29 Million dollars as of 13 April 2023. Dr Kim owns over 120,000 units of Cymabay Therapeutics Inc stock worth over $4,294,473 and over the last 10 years he sold CBAY stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dr MBA CBAY stock SEC Form 4 insiders trading

Dr has made over 7 trades of the Cymabay Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 120,000 units of CBAY stock worth $524,400 on 13 April 2023.

The largest trade he's ever made was exercising 120,000 units of Cymabay Therapeutics Inc stock on 13 April 2023 worth over $524,400. On average, Dr trades about 13,340 units every 185 days since 2015. As of 13 April 2023 he still owns at least 132,219 units of Cymabay Therapeutics Inc stock.

You can see the complete history of Dr Kim stock trades at the bottom of the page.

Dr. Dennis D. Kim M.B.A., M.D., MBA biography

Dr. Dennis D. Kim M.B.A., M.D., MBA is the Chief Medical Officer at Cymabay Therapeutics Inc.

How old is Dr MBA?

Dr MBA is 51, he's been the Chief Medical Officer of Cymabay Therapeutics Inc since . There are 11 older and 3 younger executives at Cymabay Therapeutics Inc. The oldest executive at Cymabay Therapeutics Inc is Robert Wills, 66, who is the Independent Chairman of the Board.

What's Dr MBA's mailing address?

Dennis's mailing address filed with the SEC is C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK, CA, 94560.

Insiders trading at Cymabay Therapeutics Inc

Over the last 10 years, insiders at Cymabay Therapeutics Inc have traded over $17,635,452 worth of Cymabay Therapeutics Inc stock and bought 2,170,647 units worth $6,725,086 . The most active insiders traders include Capital Advisors Llc Aghaza..., Kurt Von Emster, and Carl Goldfischer. On average, Cymabay Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $1,796,241. The most recent stock trade was executed by Sujal Shah on 13 March 2024, trading 139,119 units of CBAY stock currently worth $656,642.

What does Cymabay Therapeutics Inc do?

cymabay therapeutics is a clinical-stage biopharmaceutical company located in the san francisco bay area focused on developing therapies to treat metabolic diseases with high unmet medical need or serious rare and orphan diseases. we are committed to developing breakthrough medicines that improve the lives of patients and their families. cymabay was seeded with the assets from an earlier metabolic disease company in which more than $120m was invested to produce a robust pipeline.

Complete history of Dr Kim stock trades at Cymabay Therapeutics Inc and Zafgen

Cymabay Therapeutics Inc executives and stock owners

Cymabay Therapeutics Inc executives and other stock owners filed with the SEC include:

• Sujal Shah,
  President, Chief Executive Officer, Director
• Charles McWherter,
  Senior Vice President, Chief Scientific Officer
• Klara Dickinson,
  Chief Regulatory and Compliance Officer
• Daniel Menold,
  Vice President - Finance
• Sujal A. Shah,
  Pres, CEO & Director
• Dr. Charles A. McWherter Ph.D.,
  Chief Scientific Officer
• Paul T. Quinlan,
  Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Robert Wills,
  Independent Chairman of the Board
• Kurt von Emster,
  Independent Director
• Paul Truex,
  Independent Director
• Caroline Loewy,
  Independent Director
• Dr. Dennis D. Kim M.B.A., M.D., MBA,
  Chief Medical Officer
• Becki Filice,
  Sr. VP of Portfolio & Product Leadership
• Klara A. Dickinson-Eason,
  Chief Regulatory & Quality Assurance Officer
• Dr. Robert L. Martin,
  Sr. VP of Manufacturing & Nonclinical Devel.
• Patrick J. O'Mara,
  Sr. VP of Bus. Devel.
• Ken Boehm,
  Sr. VP of HR
• Daniel Menold,
  VP of Fin.
• Evan A. Stein,
  Director
• Robert F. Booth,
  Director
• Carl Goldfischer,
  Director
• Pol F Boudes,
  Chief Medical Officer
• Robert J. Weiland,
  Director
• Kirk Rosemark,
  V.P. Regulatory & Quality
• Wart Harold Van,
  President and CEO
• Emster Kurt Von,
  Director
• Thomas G Wiggans,
  
• Paul T Quinlan,
  General Counsel
• Eric Lefebvre,
  
• Harish Shantharam,
  Chief Financial Officer
• Lewis J Stuart,
  Chief Commercial Officer
• Patrick J. O Mara,
  VP, Business Development
• Robert L. Martin,
  Sr. Vice President
• Capital Advisors Llc Aghaza...,
  
• Edward Penhoet,
  Director
• Louis G Lange,
  Director
• Hari Kumar,
  Director
• Janet Dorling,
  
• Dennis D Kim,
  Chief Medical Officer